Government funds medicine for aggressive lymphoma
Federal Government funding for a new cancer medicine to treat an aggressive form of lymphoma is being welcomed by medical experts, patients and their families.
The Federal Minister for Health today announced that from 1 August 2018, IMBRUVICA® (ibrutinib) will become the first oral medicine subsidised through the Pharmaceutical Benefits Scheme (PBS) for Australians with Mantle Cell Lymphoma (MCL) whose condition progresses after initial chemotherapy-based treatment.
The new subsidy will make treatment with IMBRUVICA affordable for hundreds of Australians each year with relapsed or refractory MCL, who face an average survival of only one-to-two years.
Doctors, patients and Lymphoma Australia representatives are available for interview. ---
/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s). View in full here.
